Administrative Court Error Complicates Infarmed Vaccine Data Transparency

By João L. Carapinha

February 23, 2026

Infarmed vaccine data transparency

Court Clerical Error Threatens Infarmed Vaccine Data Transparency

Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court’s secretariat, which sent a January 16 dispatch from Judge Ana de Campos to PÁGINA UM’s former lawyer. This misstep interpreted the outlet’s silence on Infarmed’s compliance with a data release order as implicit confirmation, potentially allowing Infarmed to evade full disclosure of COVID-19 vaccine pharmacovigilance data. Despite PÁGINA UM’s prompt reply, the judge may deem the matter moot, extending litigation and highlighting delays in accessing adverse reaction reports from vaccines and Remdesivir.

Gaps in Released Vaccine Data

Partial pharmacovigilance data from Infarmed, released in August 2024 and covering only December 2020 to December 2021, reveals critical omissions like causality grading, dose numbers, batch details, age, municipality, and notifier profession. Of 27,220 adverse reactions, 7,110 were serious, including 104 deaths—such as an 80+ year-old woman dying two minutes after Pfizer vaccination and a man from pulmonary thromboembolism 15 minutes post-dose. Under-25s saw 513 serious reactions (225 without follow-up), plus nine deaths in the 25-49 group. Broader Portal RAM data to August 2024 showed 19,224 of 45,337 entries (42.4%) with “unknown” outcomes, including myocarditis/pericarditis, anaphylaxis, embolisms, Guillain-Barré, strokes, thromboses, and infarctions.

PÁGINA UM’s December 6, 2021, request for Remdesivir and COVID-19 vaccine data was denied by Infarmed under Rui Santos Ivo, leading to the Commission on Access to Administrative Documents. On March 16, 2022, it ordered anonymized release, rejecting refusals. Infarmed’s non-compliance triggered summons, a March 2023 overturned ruling, and a July 11, 2024, Tribunal Central Administrativo do Sul order for full data. Infarmed’s truncated response prompted PÁGINA UM’s July 2024 fine request (€200 minimum daily on Ivo).

Reference url

Recent Posts

Portugal Biotech Growth
Catalysts Driving Portugal Biotech Growth in Europe

By João L. Carapinha

July 2, 2026

Portugal Biotech Growth is reshaping the country’s standing in European life sciences, delivering a compact yet high-potential ecosystem anchored by world-class universities in Porto and Coimbra, innovation parks, and forward-looking industrial policy. Once overshadowed by larger neighbours, Port...
Shingles vaccine affordability
Shingles Vaccine Affordability and Its Impact on Public Health in South Africa

By João L. Carapinha

July 2, 2026

Shingles vaccine affordability remains a pressing concern as the recombinant zoster vaccine launches in South Africa. This vaccine delivers substantially higher efficacy and longer protection against herpes zoster and post-herpetic neuralgia than the live attenuated version withdrawn in 2024, yet...
health innovation access
Widespread Barriers to Health Innovation Access in Portugal

By João L. Carapinha

July 2, 2026

Health innovation access in Portugal is widely viewed as inadequate, with 80% of patient associations rating it as reasonable or poor. Only 14% say most relevant innovations reach patients without significant restrictions, according to a Medjournal.pt investigation. The gaps are most acute in ...